Table 2.
Clinicopathological characteristics after propensity adjustment.
| Characteristics | Systemic Nodal Dissection | Lobe-Specific Nodal Dissection | p |
|---|---|---|---|
| n = 219 | n = 219 | ||
| Age (years old), | 67 | 66 | 0.69 |
| Median, IQR | (61–72) | (61–72) | |
| Sex, male (%) | 131 (59.8%) | 132 (60.3%) | 0.92 |
| Smoking history, | 30.0 | 35.0 | 0.64 |
| pack-year (median, IQR) | (0–52.0) | (0–51.0) | |
| Carcinoembryonic antigen (ng/mL) | 8.9 | 8.3 | 0.82 |
| median, IQR | (6.2–19.2) | (6.5–17.0) | |
| Clinical stage n (number, %) | 0.83 | ||
| cN0 | 154 (70.3%) | 156 (71.2%) | |
| cN1-2 | 65 (29.7%) | 63 (28.8%) | |
| Histology (number, %) | 0.36 | ||
| Adenocarcinoma | 153 (69.9%) | 162 (74.0%) | |
| Squamous | 39 (17.8%) | 33 (15.1%) | |
| Others | 27 (12.3%) | 24 (10.9%) | |
| Surgical approach (number, %) | 0.64 | ||
| Thoracoscopy | 25 (9.4%) | 22 (10.0%) | |
| Thoracotomy | 194 (90.6%) | 197 (90.0%) | |
| Type of procedure (number, %) | 0.76 | ||
| Lobectomy | 213 (97.3%) | 214 (97.7%) | |
| Pneumonectomy/bilobectomy | 6 (2.7%) | 5 (2.3%) | |
| Adjuvant chemotherapy ± Radiotherapy (yes, %) |
88 (40.2%) | 86 (39.3%) | 0.85 |
| Pathological stage | 0.29 | ||
| IA1/IA2/IA3/IB | 5/19/14/34 | 3/21/11/46 | |
| IIA/IIB | 8/49 | 12/47 | |
| IIIA/IIIB | 75/15 | 69/10 | |
| Mutation status | 0.77 | ||
| EGFR or ALK positive | 83 (37.9%) | 86 (39.3%) | |
| No mutations or uninformative | 136 (62.1%) | 133 (60.7%) |
IQR, interquartile range; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase.